Eflapegrastim

Eflapegrastim, sold under the brand names Rolvedon among others, is a long-acting G-CSF analog developed by Hanmi Pharmaceutical and licensed to Spectrum Pharmaceuticals.[2] Eflapegrastim is a leukocyte growth factor.[1] It is used to reduce the risk of febrile neutropenia in people with non-myeloid malignancies receiving myelosuppressive anti-cancer agents.[1][3]

Eflapegrastim
Clinical data
Trade namesRolvedon
Other namesEflapegrastim-xnst, HM-10460A, SPI-2012
Routes of
administration		Subcutaneous
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • None
UNII
KEGG

Eflapegrastim was approved for medical use in the United States in September 2022.[1][4][5]

Medical uses

Eflapegrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.[1]

Its efficacy has been shown to be non-inferior to pegfilgrastim.[1]

References
  1. "Rolvedon- eflapegrastim-xnst injection, solution". DailyMed. 23 September 2022. Retrieved 16 October 2022.
  2. pharmaceutical, hanmi. "Pipeline - R&D". Hanmi Pharmaceutical. Archived from the original on 2 February 2017. Retrieved 23 January 2017.
  3. Blayney DW, Schwartzberg L (September 2022). "Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review". Cancer Treatment Reviews. 109: 102427. doi:10.1016/j.ctrv.2022.102427. PMID 35785754.
  4. "Rolvedon: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 19 September 2022. Retrieved 18 September 2022.
  5. "Spectrum Pharmaceuticals Receives FDA Approval for Rolvedon (eflapegrastim-xnst) Injection". Business Wire (Press release). 9 September 2022. Archived from the original on 9 September 2022. Retrieved 18 September 2022.
  • "Eflapegrastim". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02643420 for "SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) (ADVANCE)" at ClinicalTrials.gov
  • Clinical trial number NCT02953340 for "SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.